Harmony Biosciences Holdings, Inc. (HRMY) saw its stock soar 5.17% in pre-market trading on Tuesday following the release of its impressive first-quarter 2025 financial results. The rare neurological disease-focused pharmaceutical company reported earnings that surpassed analysts' expectations and reaffirmed its full-year revenue guidance.

The company reported adjusted earnings of $1.03 per diluted share for Q1, significantly beating the FactSet consensus estimate of $0.83. This represents a substantial increase from $0.88 per share in the same quarter last year. Harmony's Q1 revenue also exceeded expectations, coming in at $184.7 million compared to analysts' projections of $182.3 million. The strong top-line performance was driven by product revenue of $184.733 million, surpassing the IBES estimate of $182.9 million.

Harmony Biosciences demonstrated solid profitability metrics, with a gross profit of $152.739 million and operating income of $56.245 million for the quarter. The company's pretax profit of $57.177 million notably outperformed the IBES estimate of $46 million. Adding to investor confidence, Harmony reaffirmed its full-year 2025 revenue guidance, projecting net product revenue between $820 million and $860 million, in line with analysts' expectations of $840.4 million. This positive outlook, combined with the strong Q1 performance, likely contributed to the stock's pre-market rally.